Wolverine Legal Status leaves a pharmacy’s permission unsettled

Wolverine legal status is unresolved after sponsors withdrew ingredient requests

What does Wolverine legal status mean for a patient? The mixture lacks drug approval, and pharmacy permission remains unsettled. Since 2023, both ingredients have left FDA's risk group, Category 2. Sponsors, the people who proposed the ingredients, withdrew their requests to allow pharmacy use. Those requests concerned raw ingredients for medicine made to suit a particular patient. Withdrawal didn't give your pharmacy permission to use either ingredient.

An ingredient request and a patient's prescription are different things.

FDA's Pharmacy Compounding Advisory Committee advises on compounding, making medicine for a patient's needs, and met July 23-24, 2026 about proposed ingredients ^[10]. The discussion concerned FDA's allowed-ingredient list, rather than approval of a treatment. By September 2026, FDA hadn't published how the committee voted.

The dates on FDA's notices also need to be read carefully. Its September 29, 2023 notice assigned both ingredients to Category 2 over possible serious harm. FDA's page current as of April 22, 2026 reports the sponsors’ withdrawal of the ingredient requests ^[9]. The safety concerns are still there, and that page date doesn't say when the ingredients left the risk group.

A separate temporary group, Category 1, concerned other proposed ingredients awaiting a decision. FDA temporarily chose not to act against pharmacies breaking the raw-ingredient rule while reviewing that group. The rule still applied, along with other drug-law requirements. Category 2 ingredients didn't receive that temporary allowance because of the risks. The withdrawn requests don't show that these ingredients entered the other group. FDA has not stated what preparation is now permitted and has not approved either ingredient or the mixture ^[9].

Leaving Category 2 alone cannot settle your pharmacist's question about using these ingredients.

Athletes subject to WADA drug testing face bans on both ingredients. Those bans concern permission to compete, rather than permission to prepare a patient's medicine. Your doctor and pharmacist face the medicine question.

FDA 503A pharmacy rules require more than a prescription

A patient's prescription doesn't make every raw ingredient eligible for use. The law called Section 503A covers pharmacies and doctors making medicine for a particular patient. Such medicine generally needs a valid prescription. Section 503B concerns registered facilities where medicine is prepared in larger batches under FDA manufacturing rules ^[9]. Your pharmacy and a larger-batch facility therefore work under different parts of the law.

Raw ingredients must still meet the legal requirements for the kind of preparation involved.

For a patient's medicine, an ingredient can qualify in one of three ways. An official drug quality standard is one route; use in an FDA-approved drug is another. Placement on the FDA list of allowed ingredients is the third route. Quality standards concern the correct ingredient, the amount and unwanted substances. FDA considers proposed additions with advice from its pharmacy committee ^[9]. None of those routes has been clearly established here as permission for your medicine.

FDA's temporary policy was separate from that allowed list. The policy's Category 1 covered ingredients awaiting a decision; FDA temporarily held off acting over the raw-ingredient rule, without changing the rule. Other requirements still applied, while Category 2 covered ingredients with possible serious risks and had no such allowance ^[9]. Both requests are withdrawn, and the ingredients are outside Category 2.

For BPC-157, FDA's September 29, 2023 notice raised concerns about the immune system, the body's defenses, treating the substance as foreign and reacting. FDA examined BPC-157 alone and BPC-157 acetate, a form joined to another chemical. The acetate form is called a salt; here that means a chemical pairing, rather than table salt. Listing the forms in Category 2 did not declare either safe or permit pharmacy use. FDA also warned about difficulties checking the active ingredient and unwanted substances. These were concerns about testing contents, rather than findings about a particular bottle. FDA's page dated April 22, 2026 still gives those concerns beside the withdrawn request ^[9].

FDA's September 29, 2023 notice also put TB-500 in Category 2. It described TB-500 as part of Thymosin beta-4 and raised concerns about immune reactions and missing safety evidence ^[9]. The TB-500 description concerns the short substance, distinct from whole Thymosin Beta-4 used in many studies ^[9]. Withdrawal has not supplied a clear answer for your pharmacist.

The July 2026 meeting was advice rather than a final permission decision

What did the meeting settle? No final permission to prepare either ingredient was published. FDA's Pharmacy Compounding Advisory Committee met July 23-24, 2026 about ingredients for compounding: medicine made for a patient's particular needs ^[10]. BPC-157 and TB-500 were outside Category 2 after their sponsors withdrew the requests. At the July 23-24, 2026 meeting, FDA staff said neither ingredient belonged on the allowed-ingredient list. By September 2026, FDA hadn't published how committee members voted ^[9][10].

Your pharmacy cannot treat a discussion as permission to make medicine with these ingredients.

FDA makes the final list decision through proposed and final rules, with public comments between ^[9]. The committee's advice is part of considering an ingredient, rather than a final decision. FDA hadn't published an outcome for the July 23-24, 2026 discussion. Those dates tell when the meeting occurred, without establishing any change in pharmacy permission. Neither discussion nor withdrawal establishes safety for your treatment.

Your medical assessment and the pharmacy’s legal duties remain separate

A licensed prescriber, such as a doctor legally allowed to write prescriptions, assesses the patient's health first. The prescriber weighs whether that patient needs specially prepared medicine before writing the prescription ^[9]. A pharmacy following Section 503A makes medicine for a particular patient's needs. A registered Section 503B facility prepares larger batches under different drug-law requirements ^[9]. An assessment may happen by phone or video. Your kind of appointment cannot change the rules on ingredients available to the pharmacy ^[9].

A medical visit cannot resolve the missing FDA answer about these ingredients.

The pharmacist still needs to establish that each ingredient meets the rules. FDA has not explained pharmacy permission for BPC-157 and TB-500 after their sponsors withdrew the requests ^[9]. The published safety concerns remain. Rules for one patient's medicine differ from rules for larger batches, but both kinds of preparation face ingredient limits. Your assessment asks whether medicine suits your health. That medical judgment cannot replace a clear legal answer about whether the ingredients may be prepared.

Wolverine lacks drug approval and remains banned in tested sport

FDA treatment approval is absent for each ingredient and for the pair. The ingredients are supplied for laboratory research ^[9]. Their sponsors withdrew the requests, leaving both outside Category 2, the risk group. FDA still leaves the pharmacist without a stated answer about preparation after withdrawal ^[9]. WADA's sport drug rules still ban both ingredients during and between competitions.

BPC-157 pharmacy permission remains unanswered after the meeting

FDA has not clearly answered whether a pharmacy may prepare BPC-157. The September 29, 2023 notice put the ingredient in Category 2 because of possible serious risks. Its sponsor later withdrew the request without obtaining stated permission ^[9]. The July 23-24, 2026 meeting considered BPC-157 for the allowed-ingredient list. FDA staff opposed adding it; the votes remained unpublished in September 2026 ^[10]. Your pharmacist still needs that legal answer.

FDA 503A permission cannot be assumed from the withdrawn requests

The ingredients entered FDA's risk group, Category 2, in September 2023. FDA's page dated April 22, 2026 reports the sponsors’ withdrawal of the ingredient requests ^[9]. Withdrawal doesn't establish permission for medicine prepared for one patient's needs. The July 23-24, 2026 meeting considered BPC-157 and TB-500 for the allowed-ingredient list. FDA staff opposed both; the votes weren't published by September 2026 ^[10]. Your pharmacist cannot treat withdrawn requests as an added ingredient on that list.

BPC-157 and TB-500 bans apply to athletes covered by sport drug rules

FDA has granted no treatment approval for the ingredients or their combination. WADA bans BPC-157 as an unapproved substance. TB-500 / Thymosin Beta-4 falls under bans concerning growth and tissue repair. FDA assigned the ingredients to its risk group, Category 2, in 2023 ^[9]. Sport eligibility cannot answer your pharmacy's question about the ingredients.